Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

mAbs

Volumn 8, Issue 1, 2016, Pages 141-149

  Silacci, Michela ^a   Lembke, Wibke ^a   Woods, Richard ^a   Attinger Toller, Isabella ^a   Baenziger Tobler, Nadja ^a   Batey, Sarah ^a   Santimaria, Roger ^a   von der Bey, Ulrike ^a   Koenig Friedrich, Susann ^a   Zha, Wenjuan ^a   Schlereth, Bernd ^a   Locher, Mathias ^a   Bertschinger, Julian ^a   Grabulovski, Dragan ^a  

^a JOHNSON AND JOHNSON   (United States)

Author keywords

Bispecific antibody; FynomAb; IL 17; Inflammatory diseases; TNF

Indexed keywords

BISPECIFIC ANTIBODY; IL17A PROTEIN, HUMAN; INTERLEUKIN 17; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; FEMALE; HUMAN; IMMUNOLOGY; MALE; MOUSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PSORIASIS;

ANIMALS; ANTIBODIES, BISPECIFIC; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INTERLEUKIN-17; MALE; MICE; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84964413447     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1093266     Document Type: Article

References (25)

1. Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Therapy 2014; 16:R56; http://dx.doi.org/10.1186/ar4491
2. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Therapy 2009; 11 Suppl 1:S1; http://dx.doi.org/10.1186/ar2666
3. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73:492-509; PMID:24161836; http://dx.doi.org/10.1136/annrheumdis-2013-204573
4. Geiler J, Buch M, McDermott MF. Anti-TNF treatment in rheumatoid arthritis. Curr Pharmaceutical Design 2011; 17:3141-54; http://dx.doi.org/10.2174/138161211798157658
5. Villeneuve E, Haraoui B. To switch or to change classthe biologic dilemma in rheumatoid arthritis. Nat Rev Rheumatol 2010; 6:301-5; PMID:20386564; http://dx.doi.org/10.1038/nrrheum.2010.45
6. Benedetti G, Miossec P. Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur J Immunol 2014; 44:339-47; PMID:24310226; http://dx.doi.org/10.1002/eji. 201344184
7. Koenders MI, Marijnissen RJ, Devesa I, Lubberts E, Joosten LA, Roth J, van Lent PL, van de Loo FA, van den Berg WB. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1beta, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum 2011; 63:2329-39; PMID:21520013; http://dx.doi. org/10.1002/art.30418
8. Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K, Jawad A, Pathan E, Kinderlerer A, Taylor PC, et al. Incomplete response of inflammatory arthritis to TNFalpha blockade is associated with the Th17 pathway. Ann Rheum Dis 2012; 71:1741-8; PMID:22550316; http://dx.doi.org/10.1136/annrheumdis-2011-201024
9. Grabulovski D, Kaspar M, Neri D. A novel, nonimmunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J Biol Chem 2007; 282:3196-204; PMID:17130124; http://dx.doi.org/10.1074/jbc.M609211200
10. Bertschinger J, Grabulovski D, Neri D. Selection of single domain binding proteins by covalent DNA display. Protein Eng Des Sel 2007; 20:57-68; PMID:17242027; http://dx.doi.org/10.1093/protein/gzl055
11. Schlatter D, Brack S, Banner DW, Batey S, Benz J, Bertschinger J, Huber W, Joseph C, Rufer A, van der Klooster A, et al. Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain. MAbs 2012; 4:497-508; PMID:22653218; http://dx.doi.org/10.4161/mabs.20452
12. Banner DW, Gsell B, Benz J, Bertschinger J, Burger D, Brack S, Cuppuleri S, Debulpaep M, Gast A, Grabulovski D, et al. Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones. Acta Crystallogr D Biol Crystallogr 2013; 69:1124-37; PMID:23695257; http://dx.doi.org/10.1107/S0907444913006574
13. Brack S, Attinger-Toller I, Schade B, Mourlane F, Klupsch K, Woods R, Hachemi H, von der Bey U, Koenig-Friedrich S, Bertschinger J, et al. A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action. Mol Cancer Therapeutics 2014; 13:2030-9; http://dx.doi.org/10.1158/1535-7163.MCT-14-0046-T
14. Silacci M, Baenziger-Tobler N, Lembke W, Zha W, Batey S, Bertschinger J, Grabulovski D. Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency. J Biol Chem 2014; 289:14392-8; PMID:24692552; http://dx.doi.org/10.1074/jbc.M113.534578
15. Urech DM, Feige U, Ewert S, Schlosser V, Ottiger M, Polzer K, Schett G, Lichtlen P. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF{a} single-chain Fv antibody (ESBA105) designed for local therapeutic use. Ann Rheum Dis 2010; 69:443-9; PMID:19293161; http://dx.doi.org/10.1136/ard.2008.105775
16. Gerhardt S, Abbott WM, Hargreaves D, Pauptit RA, Davies RA, Needham MR, Langham C, Barker W, Aziz A, Snow MJ, et al. Structure of IL-17A in complex with a potent, fully human neutralizing antibody. J Mol Biol 2009; 394:905-21; PMID:19835883; http://dx.doi.org/10.1016/j.jmb.2009.10.008
17. Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, Prabhu S. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{a} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 2010; 38:600-5; PMID:20071453; http://dx. doi.org/10.1124/dmd.109.031310
18. Fischer JA, Hueber AJ, Wilson S, Galm M, Baum W, Kitson C, Auer J, Lorenz SH, Moelleken J, Bader M, et al. Combined Inhibition of Tumor Necrosis Factor a and Interleukin-17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody. Arthritis Rheumatol 2015; 67:51-62; PMID:25303306; http://dx.doi.org/10.1002/art. 38896
19. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P, Study G. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50:1412-9; PMID:15146410; http://dx. doi.org/10.1002/art.20221
20. Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, Chen D, Becker JC. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007; 66:228-34; PMID:16935912; http://dx.doi.org/10.1136/ard.2006.055111
21. Thomaidis T, Worns MA, Galle PR, Mohler M, Schattenberg JM. Treatment of malignant ascites with a second cycle of catumaxomab in gastric signet cell carcinoma - a report of 2 cases. Oncology Res Treatment 2014; 37:674-7; http://dx.doi.org/10.1159/000365597
22. Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2014; 16(1):57-66; PMID:25524800; http://dx.doi. org/10.1016/S1470-2045(14)71170-2
23. Muller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy: Current perspectives. Bio-Drugs 2010; 24:89-98; PMID:20199124; http://dx. doi.org/10.2165/11530960-000000000-00000
24. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx. doi.org/10.1038/nbt1345
25. Viti F, Nilsson F, Demartis S, Huber A, Neri D. Design and use of phage display libraries for the selection of antibodies and enzymes. Methods Enzymol 2000; 326:480-505; PMID:11036659; http://dx.doi.org/10.1016/S0076-6879(00)26071-0